Patents by Inventor Gary A. Truitt

Gary A. Truitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vitamin D3 analogs
    Patent number: 5145846
    Abstract: Compounds of the formula ##STR1## wherein R is hydrogen or hydroxy, R.sub.5 is hydrogen, and A is ##STR2## with the proviso that when A is --C.tbd.C--, R.sub.5 may also be deuterium, are described.The compounds of formula I are useful as agents for the treatment of hyperproliferative disorders of the skin such as psoriasis, as agents for the treatment of neoplastic diseases such as leukemia, and as agents for the treatment of sebaceous gland diseases such as acne or seborrheic dermatitis.
    Type: Grant
    Filed: April 10, 1991
    Date of Patent: September 8, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, deceased, Bernard M. Hennessy, Shian-Jan Shiuey, Gary A. Truitt, Milan R. Uskokovic
  • Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
    Patent number: 5120722
    Abstract: The compounds 1.alpha.,25(S), 26-trihydroxy-.DELTA..sup.22 -cholecalciferol; 1.alpha.,25(R), 26-trihydroxy-.DELTA..sup.22 -cholecalciferol; 1.alpha.,25(S),26-trihydroxyergocalciferol, 1.alpha.,25(R),26-trihydroxyergocalciferol and pharmaceutical compositions comprising the compounds as well as methods of making and using these compounds are disclosed.
    Type: Grant
    Filed: March 19, 1990
    Date of Patent: June 9, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Andrew D. Batcho, Gary A. Truitt, Milan R. Uskokovic, Peter M. Wovkulich
  • Compounds, process and intermediates
    Patent number: 5110958
    Abstract: The claimed invention relates to intermediate compounds of the formula ##STR1## wherein R is hydrogen or methyl, R.sub.1 and R.sub.2 each, independently, is hydrogen, lower alkyl or aryl, or taken together are lower alkylene of from 3 to 6 carbon atoms, and the dotted (. . . ) line is an optional bond.
    Type: Grant
    Filed: May 6, 1991
    Date of Patent: May 5, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Andrew D. Batcho, Gary A. Truitt, Milan R. Uskokovic, Peter M. Wovkulich
  • Vitamin D.sub.3 analogs
    Patent number: 5087619
    Abstract: Compounds of the formula ##STR1## wherein R is hydrogen or hydroxy, R.sub.5 is hydrogen, and A is --C.tbd.C--, ##STR2## or --CH.sub.2 --CH.sub.2 --, with the proviso that when A is --C.tbd.C--, R.sub.5 may also be deuterium, are described.The compounds of formula I are useful as agents for the treatment of hyperproliferative disorders of the skin such as psoriasis, as agents for the treatment of neoplastic diseases such as leukemia, and as agents for the treatment of sebaceous gland diseases such as acne or seborrheic dermatitis.
    Type: Grant
    Filed: March 23, 1990
    Date of Patent: February 11, 1992
    Assignee: Hoffman-La Roche Inc.
    Inventors: Enrico G. Baggiolini, deceased, Barbara J. Baggiolini, Bernard M. Hennessy, Shian-Jan Shiuey, Gary A. Truitt, Milan R. Uskokovic
  • Trifluorinated-1.alpha.,25S-dihydroxy vitamin D3 compounds
    Patent number: 5039671
    Abstract: 26, 26, 26-Trifluoro-1.alpha., 25-dihydroxy-cholecalciferol, and the 25R or 25S epimer thereof, are described, as well as processes and intermediates utilized to prepare the same, as well as pharmaceutical compositions containing the same. 26,26,26-trifluoro 1.alpha., 25-dihydroxycholecalciferol and the 25R or 25S epimer thereof are useful agents in the treatment of disease states such as osteoporosis, oseodystrophy and leukemia.
    Type: Grant
    Filed: November 16, 1989
    Date of Patent: August 13, 1991
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Giacomo Pizzolato, Gary A. Truitt, Milan R. Uskokovic
  • Novel trifluorinated vitamin D3 intermediates
    Patent number: 4906785
    Abstract: 26,26,26-Trifluoro-1.alpha.,25-dihydroxy-cholecalciferol, and the 25R or 25S epimer thereof, are described, as well as processes and intermediates utilized to prepare the same, as well as pharmaceutical compositions containing the same. 26,26,26-trifluoro 1.alpha.,25-dihydroxycholecalciferol and the 25R or 25S epimer thereof are useful agents in the treatment of disease states such as osteoporosis, osteodystrophy and leukemia.
    Type: Grant
    Filed: January 22, 1986
    Date of Patent: March 6, 1990
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Giacomo Pizzolato, Gary A. Truitt, Milan R. Uskovic
  • Vitamin D compounds
    Patent number: 4804502
    Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydrogen or fluorine are described. The compounds of formula I are useful as agents in the treatment of disease states characterized by metabolic calcium deficiencies. Examplary of such disease states are osteoporosis and renal osteodystrophy.
    Type: Grant
    Filed: January 20, 1988
    Date of Patent: February 14, 1989
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, John J. Partridge, Shian-Jan Shiuey, Gary A. Truitt, Milan R. Uskokovic
  • Immunosuppressive agents
    Patent number: 4749710
    Abstract: The invention relates to pharmaceutical compositions comprising at least one Vitamin D derivative and a method of using the pharmaceutical compositions in suppressing immune responses.
    Type: Grant
    Filed: May 1, 1985
    Date of Patent: June 7, 1988
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Gary A. Truitt, William R. Benjamin, Bruce H. Devens, Maurice K. Gately
  • Fluorinated vitamin D.sub.3 compounds
    Patent number: 4613594
    Abstract: Novel hexafluoro-cholecalciferol compounds and processes for preparing such compounds are disclosed. Intermediates utilized in the preparation of such compounds and pharmaceutical preparations containing these compounds are also disclosed.
    Type: Grant
    Filed: November 16, 1984
    Date of Patent: September 23, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico Baggiolini, Giacomo Pizzolato, Milan Uskokovic, Gary Truitt
  • 25,26-Dehydro-1.alpha.,23(S,R)-dihydroxycholecalciferol and its epimers
    Patent number: 4612308
    Abstract: The syntheses of 25,26-dehydro-1.alpha.,23S-dihydroxycholecalciferol, 25,26-dehydro-1.alpha.,23R-dihydroxycholecalciferol, and the epimeric mixture thereof which are useful as differentiation inducing agents and anti-proliferation agents are described, 25,26-dehydro-1.alpha.,23S-dihydroxycholecalciferol 25,26-dehydro-1.alpha.,23R-dihydroxycholecalciferol and the epimeric mixture thereof are useful for treating tumors and leukemia, and osteoporosis.
    Type: Grant
    Filed: November 29, 1984
    Date of Patent: September 16, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Enrico G. Baggiolini, Gary A. Truitt, Milan R. Uskokovic, Peter M. Wovkulich
  • 25,26-dehydro-1.alpha.,24R-dihydroxycholecalciferol and 25,26-dehydro-1.alpha.,24S-dihydroxycholecalciferol and the epimeric mixture
    Patent number: 4594340
    Abstract: The syntheses of 25,26-dehydro-1.alpha.,24R-dihydroxycholecalciferol and 25,26-dehydro-1.alpha.,24S-dihydroxycholecalciferol and the epimeric mixture which are useful as differentiation inducing agent and anti-proliferation agents are described. 25,26-dehydro-1.alpha.,24R-dihydroxycholecalciferol, 25,26-dehydro-1.alpha.,24S-dihydroxycholecalciferol, and the epimeric mixture are useful in treating osteoporosis, tumors and leukemia.
    Type: Grant
    Filed: November 29, 1984
    Date of Patent: June 10, 1986
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John J. Partridge, Shian-Jan Shiuey, Gary A. Truitt, Milan R. Uskokovic